Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals, Inc. (REGN)

Today's Latest Price: $555.24 USD

9.76 (-1.73%)

Updated Sep 18 4:00pm

Add REGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

REGN Stock Summary

  • REGN has a higher market value than 96.71% of US stocks; more precisely, its current market capitalization is $59,073,312,845.
  • With a year-over-year growth in debt of 211.53%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 92.72% of about US stocks.
  • Over the past twelve months, REGN has reported earnings growth of 55.02%, putting it ahead of 83.77% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Regeneron Pharmaceuticals Inc, a group of peers worth examining would be LRCX, AMD, SNPS, MU, and VRTX.
  • Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to
REGN Daily Price Range
REGN 52-Week Price Range

REGN Stock Price Chart Technical Analysis Charts

REGN Price/Volume Stats

Current price $555.24 52-week high $664.64
Prev. close $565.00 52-week low $271.37
Day low $544.96 Volume 1,977,113
Day high $567.83 Avg. volume 1,152,598
50-day MA $609.91 Dividend yield N/A
200-day MA $513.44 Market Cap 59.07B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio

Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$555.24$612.24 8%

We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 47th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 108.12; that's higher than 95.81% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 10.83% of the free cash flow producing stocks we're observing.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.6% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Regeneron Pharmaceuticals Inc? See HRC, EBS, HBIO, DXCM, and AMED.

REGN Latest News Stream

Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients

Lilly’s anti-inflammatory drug Olumiant reduced hospital stays when combined with Gilead’s remdesivir.

Yahoo | September 16, 2020

Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Yahoo | September 16, 2020

2 COVID-19 Antibody Stocks to Buy Right Now

Luckily, there are over 300 coronavirus treatment candidates currently in various stages of preclinical and clinical studies. If successful antibody therapeutics could be developed to treat and prevent SARS-CoV-2 infections, they could be game-changers in the fight against the disease that's caused worldwide economic shutdowns and killed almost 200,000 people in the U.S. alone. GlaxoSmithKline (NYSE: GSK) and Regeneron (NASDAQ: REGN) are two companies leading the way in developing prospective antibody treatments for COVID-19.

Yahoo | September 16, 2020

Regeneron Pharmaceuticals, Inc. (REGN) Management at Cantor Fitzgerald Virtual Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Cantor Fitzgerald Virtual Global Healthcare Conference September 15, 2020 10:00 A.M. ET Company Participants Israel Lowy - SVP, Translational Sciences and Oncology Justin Holko - VP and Head, IR Conference Call Participants Alethia Young - Cantor Fitzgerald Presentation Alethia Young Hey everybody, its Alethia Young here...

SA Transcripts on Seeking Alpha | September 15, 2020

Top Biotech Stocks for Q4 2020

The biotechnology industry includes companies that develop drugs and diagnostic compounds for the treatment of diseases and medical conditions. These products must go through a rigorous, costly, and time-consuming testing process before potentially obtaining approval from the U.

Yahoo | September 15, 2020

Read More 'REGN' Stories Here

REGN Price Returns

1-mo -8.30%
3-mo -11.65%
6-mo 23.52%
1-year 87.66%
3-year 28.10%
5-year 4.73%
YTD 47.87%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%
2015 32.33%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1577 seconds.